Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC-MATCH: Biomarker-Driven First-Line Treatment for Advanced Gastric/GEJ Cancer
NCT05608785Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of IBI315, osemitamab, benmelstobart, anlotinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
IBI315osemitamabbenmelstobartanlotinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05608785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608785.